Compare PAVM & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAVM | GXAI |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.8M |
| IPO Year | 2016 | 2023 |
| Metric | PAVM | GXAI |
|---|---|---|
| Price | $0.35 | $1.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 484.1K | 107.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $29,000.00 | ★ $694,278.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23205.74 |
| 52 Week Low | $0.30 | $1.00 |
| 52 Week High | $1.06 | $7.50 |
| Indicator | PAVM | GXAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 38.96 |
| Support Level | $0.31 | $1.19 |
| Resistance Level | $0.39 | $1.28 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 53.07 | 54.10 |
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.